PropertyValue
?:abstract
  • Abstract During outbreak of emerging disease, the most important aim is to discover an effective drug to save life. Consequently, a lot of effort are generally made by the industry to promote clinical trials with new drugs. Here we review evidence of the 8 most recent reports including 3 randomized controlled trials on the clinical efficacy of remdesivir in treating COVID-19 patient. We conclude that it is far too premature to identify remdesivir as a curative or life-saving intervention.
?:creator
?:doi
?:doi
  • 10.1016/j.nmni.2020.100707
?:journal
  • New_Microbes_New_Infect
?:license
  • els-covid
?:pdf_json_files
  • document_parses/pdf_json/9b302947667c8b02379c460081c483da92bf21cb.json
?:pmcid
?:pmid
?:pmid
  • 32837727.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Remdesivir investigational trials in COVID-19: a critical reappraisal
?:type
?:year
  • 2020-06-07

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/pkklt77i>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/pkklt77i>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all